The Goldman Sachs Group Upgrades Sandoz Group (OTCMKTS:SDZNY) to Strong-Buy

Sandoz Group (OTCMKTS:SDZNY) was upgraded by analysts at The Goldman Sachs Group to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other equities analysts have also commented on the stock. Royal Bank Of Canada lowered shares of Sandoz Group from a “moderate buy” rating to a “hold” rating in a report on Monday, March 23rd. Jefferies Financial Group upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. Finally, Barclays downgraded Sandoz Group from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Sandoz Group currently has an average rating of “Buy”.

Sandoz Group Price Performance

SDZNY opened at $80.29 on Wednesday. Sandoz Group has a fifty-two week low of $35.61 and a fifty-two week high of $94.15. The company’s 50 day moving average price is $81.58 and its two-hundred day moving average price is $72.60.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.